SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity

被引：38

作者：

Revesz, L ^{[1
]}

Blum, E ^{[1
]}

Di Padova, FE ^{[1
]}

Buhl, T ^{[1
]}

Feifel, R ^{[1
]}

Gram, H ^{[1
]}

Hiestand, P ^{[1
]}

Manning, U ^{[1
]}

Rucklin, G ^{[1
]}

机构：

[1] Novartis Inst Biomed Res Arthrit & Bone Metab, CH-4002 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 13期

关键词：

D O I：

10.1016/j.bmcl.2004.03.111

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Benzoylpyridines and benzophenones were synthesized and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Oral activity was found to depend upon substitution: 1,1-dimethylpropynylamine substituted benzophenone 10b (IC50: 14 nM) and pyridinoyl substituted benzimidazole 17b (IC50: 21 nM) showed highest efficacy and selectivity with ED50S of 9.5 and 8.6 mg/kg po in CIA. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：3601 / 3605

页数：5

共 50 条

[21] Substituted isoxazoles as potent inhibitors of p38 MAP kinase
Laufer, Stefan A.
Margutti, Simona
Fritz, Martina D.
[J]. CHEMMEDCHEM, 2006, 1 (02) : 197 - 207
[22] SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors
Revesz, L
Di Padova, FE
Buhl, T
Feifel, R
Gram, H
Hiestand, P
Manning, U
Zimmerlin, AG
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (11) : 1261 - 1264
[23] MAP kinase p38 inhibitors:: Clinical results and an intimate look at their interactions with p38α protein
Lee, MR
Dominguez, C
[J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) : 2979 - 2994
[24] P38 kinase inhibitors
Lloyd, AW
[J]. DRUG DISCOVERY TODAY, 2000, 5 (12) : 570 - 571
[25] Inhibitors of p38 kinase
Hanson, GJ
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (07) : 729 - 733
[26] Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR
Angell, Richard M.
Angell, Tony D.
Bamborough, Paul
Brown, David
Brown, Murray
Buckton, Jacky B.
Cockerill, Stuart G.
Edwards, Chris D.
Jones, Katherine L.
Longstaff, Tim
Smee, Penny A.
Smith, Kathryn J.
Somers, Don O.
Walker, Ann L.
Willson, Malcolm
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) : 324 - 328
[27] Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors
Sarma, Rituparna
Sinha, Sharat
Ravikumar, Muttineni
Kumar, Madala Kishore
Mahmood, S. K.
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (12) : 2870 - 2876
[28] Renal p38 MAP kinase activity in experimental diabetes
Komers, Radko
Lindsley, Jessie N.
Oyama, Terry T.
Cohen, David M.
Anderson, Sharon
[J]. LABORATORY INVESTIGATION, 2007, 87 (06) : 548 - 558
[29] Process Research and Development for Heterocyclic p38 MAP Kinase Inhibitors
Thiel, Oliver R.
Achmatowicz, Michal
Milburn, Robert M.
[J]. SYNLETT, 2012, (11) : 1564 - 1574
[30] 'Reverse' α-ketoamide-based p38 MAP kinase inhibitors
Montalban, Antonio Garrido
Boman, Erik
Chang, Chau-Dung
Ceide, Susana Conde
Dahl, Russell
Dalesandro, David
Delaet, Nancy G. J.
Erb, Eric
Gibbs, Andrew
Kahl, Jeff
Kessler, Linda
Lundstroem, Jan
Miller, Stephen
Nakanishi, Hiroshi
Roberts, Ed
Saiah, Eddine
Sullivan, Robert
Wang, Zhijun
Larson, Christopher J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5456 - 5459

← 1 2 3 4 5 →